Monday 22 Apr 2024
By
main news image

SINGAPORE (Feb 28): Singapore eDevelopment (SeD) announced Wednesday that its biomedical subsidiary, Global BioLife Inc, has completed the Zaire Ebola virus research portion for the study of a new anti-viral drug called LB2.

With fatality rates of up to 90%, Ebola is a severe viral disease transmitted from wild animals to human beings through physical contact, then spreads through human to human contact. It is considered one of the most virulent infections known.

According to SeD, the LB2 drug displayed efficacy at a much lower dose than the only widely used therapeutic agent for Ebola infection, T-705 (Favipiravir)... (Click here to read the full story.)

      Print
      Text Size
      Share